Recent studies have shown that a number of new novel markers, such as galactin-3 (Gal-3), adiponectin (APN), and irisin, are significantly changed in the clinical course of the various stages of DCM [13]. This evidence concerns the gene FNDC5 and familial dilated cardiomyopathy.